Surrozen Publishes Study In 'eLife' Highlihgitng Potential To Enhance Wnt-Signal Activation In Targeted SWEETS Bispecific Antibodies

6/12/24 8:32:38 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SRZN alert in real time by email

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches

Surrozen's current SWEETS bispecific antibodies are unique TPD technologies

Results demonstrated that the two new ASGR-targeted SWEETS bispecific antibodies enhanced Wnt-signal activation through the unique TPD platform

Get the next $SRZN alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$SRZN

Date	Price Target	Rating	Analyst
1/30/2025	$32.00	Buy	H.C. Wainwright
1/3/2025	$45.00	Neutral → Buy	Guggenheim
10/11/2021	$11.00	Buy	B of A Securities
9/15/2021	$20.00	Buy	Guggenheim
9/7/2021	$19.00	Buy	Stifel

More analyst ratings

$SRZN
Press Releases

Fastest customizable press release news feed in the world

View All

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P. Maleki, as an inducement material to acceptance of employment with Surrozen. The awards were granted under Surrozen's 2025 Equity Inducement Plan and provides for the granting of equity awards to new employees of Surrozen in

11/12/25 5:01:40 PM ET

$SRZN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Business HighlightsSurrozen remains focused on its ophthalmology pipeline, leveraging its Wnt biology expertise and antibody technologies to develop novel treatments for severe eye diseases. Key Third Quarter Events and Planned Fourth Quarter Scientific Meetings in 2025 Ophthalmology P

11/7/25 4:05:00 PM ET

$SRZN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025Surrozen Fireside Chat at 6:30 AM Pacific Time/9:30 AM Eastern Time Interested parties may access the audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A re

11/5/25 4:05:00 PM ET

$SRZN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

$SRZN
Leadership Updates

Live Leadership Updates

View All

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Bu

8/8/25 4:05:56 PM ET

$SRZN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to the Board of Directors. Surrozen's Board of Directors now includes nine members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently CFO of Chinook Therapeutics. He most recently served as CFO of Aimmune Therapeutics, Inc. overseeing t

4/5/23 8:30:00 AM ET

$SRZN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (NASDAQ:SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth "Liz" Nguyen has been appointed as Vice President and Head of Human Resources (HR). Ms. Nguyen brings over 20 years of experience in organizational design, talent recruitment, building a performance culture, planning and leadership development. "Liz is joining Surrozen at a time of tremendous growth as we advance our two lead programs into the clinic and continue our momentum and progress on our broad research pipeline," said Craig Parker, President and Chief

9/23/21 8:30:00 AM ET

$SRZN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Surrozen Publishes Study In 'eLife' Highlihgitng Potential To Enhance Wnt-Signal Activation In Targeted SWEETS Bispecific Antibodies

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$SRZN

Surrozen Publishes Study In 'eLife' Highlihgitng Potential To Enhance Wnt-Signal Activation In Targeted SWEETS Bispecific Antibodies

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$SRZN

$SRZN
SEC Filings

SEC Form SCHEDULE 13G filed by Surrozen Inc.

SEC Form 10-Q filed by Surrozen Inc.

Surrozen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

$SRZN
Insider Trading

Large owner Column Group Iii Gp, Lp bought $3,990,531 worth of shares (315,457 units at $12.65) (SEC Form 4)

SEC Form 4 filed by Chief Financial Officer Maleki Andrew Pedrum

SEC Form 3 filed by new insider Maleki Andrew Pedrum

$SRZN
Insider Purchases

Large owner Column Group Iii Gp, Lp bought $3,990,531 worth of shares (315,457 units at $12.65) (SEC Form 4)

Large owner Column Group Iii Gp, Lp bought $11,999,991 worth of shares (1,034,482 units at $11.60) (SEC Form 4)

Column Group Iii Gp, Lp bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

$SRZN
Analyst Ratings

H.C. Wainwright initiated coverage on Surrozen with a new price target

Surrozen upgraded by Guggenheim with a new price target

B of A Securities initiated coverage on Surrozen with a new price target

$SRZN
Press Releases

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Surrozen to Present at Upcoming Healthcare Investor Conference

$SRZN
Leadership Updates

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

$SRZN
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

$SRZN
Financials

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Surrozen Publishes Study In 'eLife' Highlihgitng Potential To Enhance Wnt-Signal Activation In Targeted SWEETS Bispecific Antibodies

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $SRZN

Surrozen Publishes Study In 'eLife' Highlihgitng Potential To Enhance Wnt-Signal Activation In Targeted SWEETS Bispecific Antibodies

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $SRZN

$SRZN SEC Filings

SEC Form SCHEDULE 13G filed by Surrozen Inc.

SEC Form 10-Q filed by Surrozen Inc.

Surrozen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

$SRZN Insider Trading

Large owner Column Group Iii Gp, Lp bought $3,990,531 worth of shares (315,457 units at $12.65) (SEC Form 4)

SEC Form 4 filed by Chief Financial Officer Maleki Andrew Pedrum

SEC Form 3 filed by new insider Maleki Andrew Pedrum

$SRZN Insider Purchases

Large owner Column Group Iii Gp, Lp bought $3,990,531 worth of shares (315,457 units at $12.65) (SEC Form 4)

Large owner Column Group Iii Gp, Lp bought $11,999,991 worth of shares (1,034,482 units at $11.60) (SEC Form 4)

Column Group Iii Gp, Lp bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

$SRZN Analyst Ratings

H.C. Wainwright initiated coverage on Surrozen with a new price target

Surrozen upgraded by Guggenheim with a new price target

B of A Securities initiated coverage on Surrozen with a new price target

$SRZN Press Releases

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Surrozen to Present at Upcoming Healthcare Investor Conference

$SRZN Leadership Updates

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

$SRZN Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

$SRZN Financials

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Recent Analyst Ratings for
$SRZN

Recent Analyst Ratings for
$SRZN

$SRZN
SEC Filings

$SRZN
Insider Trading

$SRZN
Insider Purchases

$SRZN
Analyst Ratings

$SRZN
Press Releases

$SRZN
Leadership Updates

$SRZN
Large Ownership Changes

$SRZN
Financials